Sangamo Therapeutics, Inc. SGMO, -5.20% today announced the completion of the acquisition of TxCell, SA. TxCell is now a subsidiary of Sangamo and has been delisted from the French stock market.
“The acquisition of TxCell immediately positions Sangamo as the leader in CAR-Treg development,” said Sandy Macrae, CEO of Sangamo. “We’re thrilled to work with our colleagues in France toward an exciting new future together developing CAR-Tregs. By combining Sangamo’s zinc finger nuclease gene editing technology with TxCell’s CAR-Treg platform, we have the potential to develop a pipeline of novel cell therapies for patients suffering from autoimmune and inflammatory disorders.”
In 2019, Sangamo expects to submit a clinical trial authorization application in Europe for TxCell’s first CAR-Treg investigational product candidate for solid organ transplant.
About the Acquisition On October 1 [st] , 2018, Sangamo acquired a majority stake in TxCell. A simplified cash tender offer was then conducted from November 1, 2018 until November 23, 2018, for the purchase of outstanding ordinary shares of TxCell. Upon completion of the simplified tender offer, on November 23, 2018, Sangamo held 95.71% of the share capital and voting rights of TxCell. On November 29, 2018, through a squeeze-out procedure, Sangamo acquired all remaining shares of TxCell.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
About Regulatory T cells (Tregs) Tregs are a naturally occurring subset of T cells and are critical for maintaining immune homeostasis within the body by induction and maintenance of tolerance to self-antigens. Sangamo intends to evaluate the potential of CAR-Tregs (Tregs genetically modified with a chimeric antigen receptor, or CAR) for the development of therapies for immunological diseases, one of Sangamo’s stated therapeutic areas of focus for its proprietary product candidate pipeline. Sangamo intends to use its zinc finger nuclease gene editing technology to develop next-generation autologous and allogeneic CAR-Treg cell therapies for use in treating autoimmune diseases such as Crohn’s disease and multiple sclerosis.
Date: December 10, 2018
Source: MarketWatch
